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Abstract
SorCS2 is an intracellular sorting receptor of the VPS10P domain receptor gene fam-
ily recently implicated in oxidative stress response. Here, we interrogated the rele-
vance of stress-related activities of SorCS2 in the brain by exploring its role in
ischemic stroke in mouse models and in patients. Although primarily seen in neurons
in the healthy brain, expression of SorCS2 was massively induced in astrocytes sur-
rounding the ischemic core in mice following stroke. Post-stroke induction was likely
a result of increased levels of transforming growth factor β1 in damaged brain tissue,
inducing Sorcs2 gene transcription in astrocytes but not neurons. Induced astrocytic
expression of SorCS2 was also seen in stroke patients, substantiating the clinical rele-
vance of this observation. In astrocytes in vitro and in the mouse brain in vivo,
SorCS2 specifically controlled release of endostatin, a factor linked to post-stroke
angiogenesis. The ability of astrocytes to release endostatin acutely after stroke was
lost in mice deficient for SorCS2, resulting in a blunted endostatin response which
coincided with impaired vascularization of the ischemic brain. Our findings identified
activated astrocytes as a source for endostatin in modulation of post-stroke
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angiogenesis, and the importance of the sorting receptor SorCS2 in this brain stress
response.
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1 | INTRODUCTION
SorCS2 is a member of the VPS10P domain receptors gene family, a
unique class of sorting receptors expressed in neurons of the mamma-
lian nervous system (Willnow, Petersen, & Nykjaer, 2008). VPS10P
domain receptors are best recognized for their ability to shuttle target
proteins between intracellular compartments and the neuronal cell
surface. By doing so, they regulate the surface exposure of neuronal
receptors or activity-dependent secretion of signaling molecules, as
shown for neurotrophin receptors or brain-derived neurotrophic fac-
tor, respectively (Z.-Y. Chen et al., 2005; Vaegter et al., 2011). The rel-
evance of neuronal protein sorting by VPS10P domain receptors is
underscored by their causal involvement in psychiatric and neurode-
generative diseases, including Huntington's disease, Alzheimer's dis-
ease, and frontotemporal dementia (Reitz, 2015; Willnow et al., 2008).
Recently, we documented that SorCS2 is unique among the vari-
ous VPS10P domain receptors as its expression is up-regulated in
response to oxidative stress and epilepsy in neurons (Malik et al.,
2019). Under these conditions, SorCS2 promotes cell surface sorting
of the neuronal amino acid transporter EAAT3, facilitating
EAAT3-mediated uptake of cysteine for production of the reactive
oxygen species scavenger glutathione (Malik et al., 2019). Ultimately,
induced expression of SorCS2 enables neurons to cope with oxidative
stress and protects them from seizure-induced cell death.
To explore a global role for SorCS2 as a stress-induced protein in
multiple brain injuries, we here assessed its significance in stroke, a path-
ological condition linked to severe oxidative stress. Surprisingly, while
up-regulation of SorCS2 expression was observed in an experimental
mouse model of stroke, this induction was specific to astrocytes, a cell
type that normally does not express this receptor. In activated astro-
cytes, SorCS2 controlled secretion of endostatin and promoted post-
stroke angiogenesis. Our findings corroborated a role for SorCS2 as a
stress-induced factor and uncovered its cell type-specific actions in pro-
tection from brain injuries, such as ischemic stroke.
2 | MATERIALS AND METHODS
2.1 | Mouse models
Mice with a targeted disruption of murine Sorcs2 (KO) have been
described (Glerup et al., 2014). KO males and wild-type littermate
controls (WT) used for in vivo studies were 8–14 weeks of age, gener-
ated by heterozygous breedings on an inbred C57BL/6N background.
Animals were kept under 12 hr/12 hr light/dark cycle with free access
to food and water. Newborn mice for astrocytic and neuronal cultures
were obtained by homozygous breeding of the respective WT or KO
strains. Animal experimentation was performed following approval
by local committees of the State of Berlin (X9012/12, X9007/17,
G 0157/17).
2.2 | Human tissue samples
Brain tissue samples used in this study for immunostainings were
obtained from the archives of the department of Neuropathology of
the Amsterdam UMC (University of Amsterdam, the Netherlands).
Three acute stroke cases (injury-death interval <2 weeks) and four
autopsy controls without any history of neurologic diseases were
included. Supporting Information Table S1 summarizes the clinical
characteristics of patients and controls. The age and gender did not
differ between stroke patients and autopsy controls (p > .05, Mann
Whitney U test). Material for primary astrocyte cultures was collected
after a written informed consent for the use of the material for
research purposes had been obtained by the Bloemenhove clinic from
all donors. All human specimens were obtained and used in accor-
dance with the Declaration of Helsinki and the Amsterdam UMC
Research Code provided by the Medical Ethics Committee of the
AMC. Local ethical committees of the participating centers gave per-
mission to undertake the study.
2.3 | Middle cerebral artery occlusion
Filamentous occlusion of the middle cerebral artery was performed as
described (Dirnagl & Members of the MCAO-SOP Group, 2012). Mice
were anaesthetized using 2.5% (vol/vol) isoflurane for induction and
1.5% (vol/vol) isoflurane for maintaining anesthesia in a mixture with
25% O2 and 75% N2O. Cerebral ischemia was induced by introducing
a 8–0 silicon-rubber coated suture (Doccol Corp., Sharon, MA) into
the left internal carotid artery and by advancing it to the anterior cere-
bral artery, thereby occluding the middle cerebral artery. The filament
was withdrawn after an occlusion time of 45 min. Body temperature
was maintained at 37.0 ± 0.5C throughout the experiment using a
feed-back controlled heating pad and a rectal probe (Fine Science
Tools GmbH, Heidelberg). During middle cerebral artery occlusion
(MCAo) and for at least 2 hr after reperfusion, animals were allowed
to recover in a heated cage (Peco Services, Cumbria, UK).
Mice were randomized and blinded for concealment of genetic
group allocation and the order of surgery. In the short-term studies
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(1 and 3 days), no mortality was observed and no mice were excluded
from analysis. In the long-term study (21 days) 4 WT (21%) and 4 KO
(20%) died within 1 week after MCAo and mice with no stroke (tech-
nical failure; 2 WT and 2 KO) or stroke volume approximately <3 mm3
(3 WT and 3 KO) were excluded from analysis.
2.4 | Brain vasculature labeling
Mice were anesthetized with Ketamine/Xylazine and a solution of
DyLight488-labeled Lycopersicon esculentum lectin (#DL-1174
Vectorlab) was injected intravenously (1 mg/ml; 4 μl per gram
bodyweight). After 180 s, mice were transcardially perfused with 4%
paraformaldehyde (PFA)/phosphate-buffered saline (PBS). Brains
were isolated and incubated in 4% PFA in PBS (overnight) and in 30%
sucrose/PBS (72 hr), and frozen in −40C isopentane prior to section-
ing. A total of 3 WT mice and 1 KO mouse were excluded from the
vessels analysis because of technical failures of lectin staining (heart
arrest during injection or bad circulation).
2.5 | Cell culture experiments
Cultures enriched in astrocytes were prepared from newborn mice
according to published protocols (Parnis et al., 2013). In brief, blood
vessels and meninges were removed from cortical tissue which was
next trypsinized and dissociated in presence of DNAse. Cells were
plated on poly-L-lysine-coated flasks and cultured in Dulbecco's Modi-
fied Eagle's Medium (DMEM) with 10% FBS and penicillin/streptomy-
cin. After 2 days, cells were washed to remove cellular debris. After
7 days in vitro, cultures were shaken extensively to remove microglia
and the astrocytes were plated for experiments.
Cells were treated with 10 ng/ml transforming growth factor β
(TGF-β1; R&D Biosystems, 7666-MB) in serum-free DMEM for 3, 6,
24, or 48 hr. Control cells were incubated in DMEM for 24 hr. For
cytokines measurements, astrocytes were stimulated with 100 nM
Phorbol 12-myristate 13-acetate (PMA) and 2.5 μM ionomycin for
3 hr or left untreated (control). For endostatin measurements, astro-
cytes were washed and incubated in serum-free DMEM for 24 hr.
Neuronal cultures were prepared from hippocampi and cortices of
newborn mice as described earlier (Malik et al., 2019). In brief, cultures
were prepared using enzymatic digestion with papain and plated at the
density of 83,000 cells/cm2. After 10 days in culture, the cells were
treated with 10 ng/ml TGF-β1 for 6, 24 or 48 hr or left untreated.
Human primary fetal astrocyte-enriched cultures were obtained
from human fetal brain tissue (14–19 weeks of gestation) obtained
from medically-induced abortions. Cells isolation was performed as
described (Aronica, Gorter, Rozemuller, Yankaya, & Troost, 2005).
Briefly, the tissue was digested with trypsin, mechanically disrupted,
and the cell suspension was plated in DMEM/Ham's F10 (1:1) medium
supplemented with penicillin/streptomycin and 10% fetal calf serum.
Cultures reached confluence after 2–3 weeks. Secondary astrocyte
cultures for experimental manipulation were used at passage 2–5.
Cells plated on poly-L-lysine-coated plates were stimulated with
human recombinant TGF-β1 (Peprotech, 10 ng/ml) for 24 hr.
2.6 | ELISA measurements
Sample preparation is described in Supporting Information. Following
enzyme-linked immunosorbent assay (ELISA) kits were used: TGF-β1
(Abcam, ab119557), GFAP (Millipore, NS830), endostatin (Boster,
EK1376), U-Plex Biomarker Group 1 assay (Meso Scale Diagnostics,
K15083K). For technical reasons, not all the samples were included in
GFAP and TGF-β1 ELISA measurements. Brain and blood plasma samples
used for endostatin measurements were selected based on the results of
tissue sections stainings and GFAP ELISA measurements to include mice
with similar lesion area and localization and comparable GFAP levels.
2.7 | Protein array
Proteome Profiler Mouse Angiogenesis Array Kit (R&D Systems,
ARY015) was used according to manufacturer's instructions. Used tis-
sue samples were selected based on the results of tissue sections
stainings and GFAP ELISA measurements to include mice with similar
lesion area and localization and comparable GFAP levels. Tissue
lysates were prepared as for ELISA, diluted in Array Buffer 6 and the
total amount of 350 μg protein was loaded on the membrane. Signal
intensities were measured with use of LI-COR Imaging System and
quantified with Image Studio Lite software. In one experiment, four
samples (WT ipsi, WT contra, KO ipsi, KO contra; ipsi and contra sam-
ples from the same mouse brain) were processed and analyzed in par-
allel. Signal intensities were normalized to the mean value obtained
for a given protein in contralateral samples (WT and KO) in the same
experiment. In total, the experiment was repeated 3 times on different
pairs (WT and KO) of mice and the results were combined.
2.8 | Immunostaining
Following antibodies were used: anti-SorCS2 (R&D Systems, AF4237,
1:100, for mouse tissue and cells; rabbit anti-SorCS2, Lifespan Biosci-
ences, LS-C501334, 1:450, for human tissue), Cy3-labeled anti-GFAP
(Sigma, C9205, 1:1,000, for mouse tissue and cells), anti-GFAP (mono-
clonal mouse, Sigma, 1:4,000, for human tissue), biotinylated anti-
NeuN (Millipore, MAB377B, 1:100, for murine tissue), mouse anti-
NeuN (Millipore, MAB377 (clone A60), 1:2,000, for human tissue).
Details on samples preparation and staining protocols are given in
Supporting Information.
2.9 | Western blot
Tissue and cell lysates were analyzed by western blot using the
following antibodies: anti-SorCS2 (R&D Systems, AF4237, 1:1,000),
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anti-p-ERK (Cell Signaling, 4370, 1:2,000), anti-actin (Abcam, ab8227,
1:2,000), anti-GFAP (Millipore, MAB360, 1:1,000). Signal was regis-
tered with digital LI-COR imaging system and quantified using the
Image Studio Lite software.
2.10 | Quantitative RT-PCR
RNA was extracted using TRIzol reagent and purified with RNeasy Mini
Kit (QIAGEN). Reversely transcribed cDNA was subjected to
quantitative real-time polymerase chain reaction (qRT-PCR) analysis. For
murine samples, following Taqman Gene Expression Assays were used:
Actb (actin, Mm02619580), GAPDH (Mm99999915), Col18a1 (collagen
XVIII, Mm00487131), and SORCS2 (Mm00473050). Col18a1 and
SorCS2 transcript levels were shown relative to Actb or GAPDH as spec-
ified in the respective figure legends. For human samples, SYBR Green
method was used with the following PCR primers: SORCS2 (forward:
GTTTGTCATCGGGCTCTTCG, reverse: GTCCTGCCTGGCCGTTTC) and
EF1a (forward: ATCCACCTTTGGGTCGCTTT, reverse: CCGCAACTGT
CTGTCTCATATCAC). SORCS2 transcript levels were given relative to
EF1α as described (Ramakers, Ruijter, Deprez, & Moorman, 2003; Ruijter
et al., 2009).
2.11 | Image analysis
Stroke lesion size was analyzed with use of ImageJ software. Lesions
and whole brain sections were marked manually based on the images
of NeuN, GFAP and DAPI stainings and their areas were measured.
For 1 KO mouse, measuring lesion size was not possible due to tech-
nical problems with sectioning. Areas covered by blood vessels were
analyzed automatically with use of Cell Profiler software. Vessels
length was analyzed manually with use of ImageJ software with Neu-
ronJ plugin. For comparison between the two hemispheres of individ-
ual mouse brains, data were normalized to the mean value obtained
for the contralateral side. For comparison between the two geno-
types, data were normalized to the mean value obtained for WT mice
analyzed in the same set.
2.12 | Statistical analysis
For in vivo experiments, an indicated number n is the number of mice
per group, and for astrocytic and neuronal culture experiments n is
the number of independent preparations (biological replicates) used.
The study was powered according to the ARRIVE guidelines to detect
differences in cytokine levels using two-way analysis of variance
(ANOVA) for side and genotype interactions with α error probe of
0.05 and Power of 0.8 and 0.7 effect size based on F tests with critical
F = 3.5 for a minimum number of n = 6 per sample size (G*Power
3.1.9.2). Statistical analyses were performed using GraphPad Prism
software. For comparison between two experimental groups, a two-
tailed unpaired t test was used with the exception of direct
comparison of TGF-β1 levels in the two hemispheres of the same
mouse brain where paired t test was used. For data with three or
more groups and one independent variable, one-way ANOVA with
Dunnett's multiple comparisons test was used. For data with two
independent variables, two-way ANOVA with Tukey's multiple com-
parisons test was applied. For ELISA and western blot quantifications,
outlier analysis was performed using Grubb's and ROUT tests and
individual datapoints were excluded accordingly. The details of statis-
tical analysis are specified in the figure legends.
3 | RESULTS
3.1 | SorCS2 is induced in astrocytes surrounding
the ischemic core
To query the significance of SorCS2 for ischemic stroke, we subjected
mice either wild-type (WT) or genetically deficient for Sorcs2 (KO) to
45 min of transient MCAo, an experimental model commonly used in
mice (Dirnagl & Members of the MCAO-SOP Group, 2012). In WT
brains 3 days after MCAo, immunostaining for neuronal (NeuN) and
astrocytic (GFAP) markers revealed severe neuronal cell loss and
astrogliosis in the ipsilateral hemisphere (Figure 1a). SorCS2 expression
in these brains was massively induced in reactive astrocytes within the
glial scar surrounding the ischemic core (region 1, Figure 1b,c) and to a
lesser extent also in other regions adjacent to the lesion (regions 2 and
4, Figure 1b,c). Little to no SorCS2 expression was seen in astrocytes in
the contralateral hemisphere (regions 3 and 5, Figure 1b,c). Induced
expression in activated astrocytes was surprising as SorCS2 expression
in the normal murine brain is predominantly seen in neuronal cell types
(Glerup et al., 2014), particularly in neurons of the hippocampal CA2
region, in pyramidal neurons of the cerebral cortex, and in striatal neu-
rons (Supporting Information Figure S1). Post-stroke induction of
SorCS2 expression was restricted to astrocytes as no overt increase in
neuronal SorCS2 immunoreactivity was seen 1 (Supporting
Information Figure S2) or 3 days after ischemic stroke (Figure 1b,c and
Supporting Information Figure S3). Similar to the situation in mouse
models, SorCS2 expression in the healthy human brain was primarily
visible in neurons and only occasionally in astrocytes (Supporting
Information Figure S4). However, SorCS2 expression was up-regulated
in astrocytes following ischemia in stroke patients, corroborating the
clinical relevance of our observations (Figure 1d).
Ischemic stroke triggers release of multiple cytokines and growth
factors that promote tissue regeneration. Of note, increased levels of
TGF-β were reported in the plasma of stroke patients (Yan, Greer, &
McCombe, 2012) and its expression was induced in the murine brain
following ischemia (Zhang et al., 2018). TGF-β has been implicated in
processes of post-stroke recovery, including glial scaring and angiogen-
esis (Meng et al., 2016; Pardali, Goumans, & ten Dijke, 2010; Zhu et al.,
2017). In line with these findings, we detected increased levels of TGF-
β1 in the ipsilateral hemispheres of the WT brains 3 days after MCAo
(Figure 2a). Application of TGF-β1 induced levels of SorCS2 transcript
(Figure 2b) and protein (Figure 2c,d) in primary murine astrocytes.
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Similarly, SorCS2 mRNA levels were also increased in cultured human
fetal astrocytes by TGF-β1 treatment (Figure 2e). By contrast, induction
was not observed in primary neurons treated with TGF-β1 (Figure 2f),
providing a possible molecular explanation for the astrocyte-specific
induction of SorCS2 expression following ischemic stroke.
3.2 | SorCS2-deficient mice show normal
post-stroke astrocyte activation and cytokines levels
To elaborate on the role of SorCS2 in activated astrocytes, we per-
formed a comparative analysis of stroke-driven astrogliosis in WT
F IGURE 1 SorCS2 expression is induced in
astrocytes after ischemic stroke. (a) Coronal brain
section of a wild-type mouse 3 days after 45 min
MCAo. Sections were immunostained for GFAP
(red; astrocytes) and NeuN (blue; neurons), and
counterstained with DAPI (grayscale). Scale bar,
1 mm. Ipsilateral (ipsi) and contralateral (contra)
hemispheres are indicated. The ischemic core is
indicated by white dashed line. Numbered yellow
dashed boxes highlight regions shown in (b).
(b) Representative images of brain sections stained
for GFAP (red; astrocytes), NeuN (blue; neurons),
SorCS2 (green), and counterstained with DAPI
(grayscale) as marked in (a). Yellow dashed boxes
indicate regions shown as higher magnification
images in (c). Maximum intensity projections of
confocal z-sections are shown. Scale bar, 50 μm.
(c) Higher magnification of regions indicated in (b).
The upper row of panels shows merged images for
GFAP (red, astrocytes), NeuN (blue, neurons), and
SorCS2 (green) immunosignals. Panels below show
the separated channels in grayscale. Robust
SorCS2 expression in GFAP-positive cells in the
glial scar region is visible. By contrast, no increase
in neuronal SorCS2 signal intensities is seen in any
of the analyzed regions of the ipsilateral as
compared to the contralateral side. The inset in
the image of the glial scar region shows a higher
magnification of SorCS2-positive astrocytes.
Maximum intensity projections of confocal
z-sections are shown. Scale bar, 50 μm. (d) SorCS2
immunostaining (brown) in the human control
brain and in the brain of a patient after stroke. The
inset in the right panel shows cells
immunofluorescently stained for SorCS2 (red) and
astrocyte marker GFAP (green) in post-stroke
brain tissue. Scale bars: overview, 100 μm;
inset, 25 μm
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animals and in mice lacking this receptor (KO). Three days after
MCAo, the size of the ischemic lesion was similar in both genotypes
(Figure 3a,b). Also, the extent of astrocyte activation in the ipsilateral
hemisphere was comparable as shown by immunodetection of GFAP
on histological sections (Figure 3a) and in brain lysates (Figure 3c,d).
Activated astrocytes drive inflammatory responses through
release of cytokines. To investigate the consequence of SorCS2 defi-
ciency on this response, we performed cytokine profiling of ipsi- and
contralateral hemispheres of WT and KO mice 3 days after MCAo.
Among the tested cytokines, IL-1β, IL-5, IL-10, IL-13, IL-16, IL-17A, IL-
17C, IL-21, IL-22, IL-23, and IFNγ showed no differences in levels
between ipsi- and contralateral hemispheres (Supporting Information -
Figure S5). GM-CSF, TNFα, KC/GRO, IL-2, MCP-1, MIP-1α, MIP-2,
IP-10, EPO, MIP-1β, MIP-3α, and IL-12p70 were up-, while VEGF-A
was down-regulated in ipsilateral as compared to contralateral hemi-
spheres (Figure 3e and Supporting Information Figure S5). However,
this response was seen in WT and KO mice to a similar extent.
3.3 | SorCS2-deficient mice fail to induce
endostatin expression after stroke
To identify factors secreted from astrocytes in a SorCS2-dependent
manner, we assayed the levels of proteins relevant for post-injury
regeneration using protein arrays. Three days after MCAo, levels of
coagulation factor III and FGF1 did not differ remarkably between
ipsi- and contralateral hemispheres (Figure 4a and Supporting
Information Figure S6). Osteopontin, CXCL4, CCN3, serpin E1, and
IGFBP2 increased in the ipsilateral hemisphere regardless of Sorcs2
genotype (Figure 4a and Supporting Information Figure S6). However,
increases in levels of IGFBP3 and endostatin in the ipsilateral hemi-
sphere were seen in WT but not KO brains, suggesting SorCS2 depen-
dency (Figure 4a–c).
The association of plasma IGFBP3 levels with SORCS2 in humans
had been reported (Kaplan et al., 2011), validating our screening
approach for identifying SorCS2 targets in the ischemic brain. Here,
we focused on endostatin, a potent anti-angiogenic factor produced
from collagen XVIII by proteolysis (Sasaki et al., 1998). Prior studies
had implicated endostatin in post-stroke recovery (Gertz et al., 2006;
Navarro-Sobrino et al., 2011). We confirmed the impact of SorCS2 on
endostatin levels by showing that endostatin levels increased twofold
in the ipsilateral as compared to the contralateral hemisphere of WT
brains at 3 days after MCAo. This effect was lost in KO mice
(Figure 4d). The rise in endostatin levels in the ipsilateral WT hemi-
sphere correlated with the lesion size (Figure 4e) and was specific to
F IGURE 2 TGF-β1 increases after ischemic stroke and induces
SorCS2 expression in primary astrocytes. (a) TGF-β1 levels in
contralateral (contra) and ipsilateral (ipsi) hemispheres of WT brains at
3 days after MCAo were determined by ELISA and normalized to total
protein content. Values obtained for individual mice are presented as
connected dots. n = 7 mice. *, p < .05 in paired t test. (b) Transcript
levels of SorCS2 in primary murine astrocytes treated with TGF-β1
(10 ng/ml) for the indicated times were measured by qRT-PCR and
given relative to transcript levels of GAPDH. Fold change relative to
untreated cells (time = 0, set to 1) is shown. Mean ± SEM is indicated.
n = 10 independent astrocytic preparations. **, p < .01 when
compared to time = 0 by one-way ANOVA with Dunett's multiple
comparisons test. (c) Western blot analysis of SorCS2 levels in primary
murine astrocytes treated with TGF-β1 (10 ng/ml) for the indicated
times in hours (h). Detection of tubulin serves as a loading control.
(d) Quantification of SorCS2 levels normalized to tubulin signal as
depicted in (c). n = 7 independent astrocytic preparations. **, p < .01,
***, p < .001 when compared to time = 0 by one-way ANOVA with
Dunett's multiple comparisons test. (e) Transcript levels of SorCS2 in
cultured human fetal astrocytes treated with TGF-β1 (10 ng/ml) for
24 hr as measured by qRT-PCR and given relative to transcript levels
of EF1α. Fold change relative to untreated cells (Ctrl, set to 1) is
shown. Mean ± SEM is indicated. n = 6 samples derived from three
donors (two replicates per donor). *, p < .05 by unpaired t test. (f)
Transcript levels of SorCS2 in primary murine neurons treated with
TGF-β1 (10 ng/ml) for the indicated times as measured by qRT-PCR
and given relative to transcript levels of actin. Fold change relative to
untreated cells (time = 0, set to 1) is shown. Mean ± SEM is indicated.
n = 6 independent neuronal preparations
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F IGURE 3 Normal glia activation and neuroinflammation in the post-stroke brain of KO mice. (a) Representative images of coronal brain
sections of WT and KO mice at 3 days after MCAo. Sections were immunostained for GFAP (red) and NeuN (green), and counterstained with
DAPI (blue). The extent of activation of GFAP-labeled astrocytes and the loss of NeuN-positive neurons in the ipsilateral (ipsi) as compared to the
contralateral (contra) side is similar in both genotypes. Scale bars, 500 μm. (b) Quantification of the stroke lesion areas on histological sections of
WT and KO brains as exemplified in (a). n = 11–12 mice per genotype. Mean ± SEM is given. (c) Western blot analysis of GFAP levels in lysates
prepared from ipsilateral (ipsi) and contralateral (contra) hemispheres of 2 WT and 2 KO mice 3 days after MCAo. Detection of SorCS2 and actin
was used as controls. (d) Levels of GFAP in ipsilateral hemispheres of WT and KO brains 3 days after MCAo were determined by ELISA. GFAP
levels were normalized to total protein content. Mean ± SEM is indicated. n = 10 mice per genotype. (e) Results of ELISA measurements of
cytokines levels in tissue lysates from ipsilateral (ipsi) and contralateral (contra) hemispheres of WT and KO brains 3 days after MCAo.
Cytokines levels were normalized to total protein content. n = 12 mice per genotype. Mean ± SEM is indicated. *, p < .05; **, p < .01; ***,
p < .001 by two-way ANOVA. See Supporting Information Figure S5 for the measurements of additional cytokines in these tissue extracts.
GM-CSF, granulocyte-macrophage colony-stimulating factor; TNFα, tumor necrosis factor alpha; KC/GRO, growth-regulated alpha protein; IL-2,
interleukin 2; MCP-1, monocyte chemoattractant protein 1; MIP-1α, macrophage inflammatory protein 1-alpha; MIP-2, macrophage inflammatory
protein 2; IP-10, interferon gamma-induced protein 10
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F IGURE 4 Endostatin levels are up-regulated after MCAo in a SorCS2-dependent manner. (a) Representative results of a proteome profiling array
performed on ipsilateral (ipsi) and contralateral (contra) brain samples fromWT and KOmice 3 days after MCAo. Each protein is detected in duplicate dots.
Encircled dots represent positive controls. Selected protein spots are labeled by numbers. 1—osteopontin, 2—serpin E1, 3—CXCL4 (C-X-Cmotif chemokine
4), 4—endostatin, 5—IGFBP2 (insulin-like growth factor-binding protein 2), 6—coagulation factor III, 7—IGFBP3 (insulin-like growth factor-binding protein 3),
8—FGF1 (fibroblast growth factor 1), 9—CCN3 (CCN family member 3). (b and c) Quantification of signal intensities for endostatin (b; spot 4 in panel (a)) and
IGFBP3 (c; spot 7 in panel (a)) obtained in proteome profiling array as depicted in (a). n = 3mice per genotype. Mean ± SEM is indicated. *, p < .05; **,
p < .01; ***, p < .001 by two-way ANOVA. See Supporting Information Figure S6 for quantifications of signal intensities for additional proteins.
(d) Endostatin levels in tissue samples from ipsilateral and contralateral hemispheres ofWT and KOmice 3 days after MCAo. Endostatin levels were
measured by ELISA and normalized to total protein content in the tissue samples. n = 6–7mice per genotype. Mean ± SEM is indicated. ***, p < .001 by
two-way ANOVAwith Tukey's multiple comparisons test. (e) Endostatin levels in the ipsilateral hemispheres inWT and KOmice 3 days afterMCAo plotted
against the respective stroke lesion sizes. R2 indicates the goodness of fit for the linear regression. n = 6–7mice per genotype. (f) Representative western
blot analysis of p-Erk levels in ipsilateral and contralateral hemispheres ofWT and KOmice 3 days afterMCAo. Detection of SorCS2 and actin is shown as
controls. (g) Quantification of p-Erk levels normalized to actin signal intensities in ipsilateral and contralateral hemispheres ofWT and KO brains as depicted
in (f). n = 9mice per genotype. Mean ± SEM is indicated. *, p < .05 by two-way ANOVAwith Tukey's multiple comparisons test
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the brain, as no changes in plasma endostatin levels were seen in
affected WT animals (Supporting Information Figure S7). Endostatin
acts on target cells through interference with signaling pathways,
including the mitogen-activated protein kinase pathway (N. Chen,
Gao, Yuan, & Zhao, 2016; Sudhakar et al., 2003). Consistent with this
fact, increased endostatin levels in the ipsilateral hemispheres of WTs
F IGURE 5 SorCS2 controls endostatin release from primary astrocytes. (a) SorCS2 expression in cultured primary astrocytes from WT and
KO mice as determined by western blotting. Each lane represents an independent astrocyte preparation. Detection of GFAP and actin was used
as loading control. (b) Representative image of immunostaining for SorCS2 (green) in primary cultured astrocytes from WT mice. Cells were co-
stained for GFAP (red) and counterstained with DAPI (blue). Combined signals (left) and SorCS2 staining in grayscale (right) are shown. Scale bar,
50 μm. (c) Cytokines levels as determined by ELISA in cell culture medium from primary WT and KO astrocytes either untreated (ctrl) or treated
with PMA/ionomycin (stim). Cytokines levels were normalized to the protein content in the respective cell lysates. n = 9 independent astrocyte
preparations per group. Mean ± SEM is indicated. *, p < .05; ***, p < .001 by two-way ANOVA. See Supporting Information Figure S8 for the
measurement of additional cytokines in these samples. TNFα, tumor necrosis factor alpha; GM-CSF, granulocyte-macrophage colony-stimulating
factor; KC/GRO, growth-regulated alpha protein; MCP-1, monocyte chemoattractant protein 1; MIP-1α, macrophage inflammatory protein
1-alpha; MIP-2, macrophage inflammatory protein 2. (d) Endostatin levels in cell medium from primary WT or KO astrocyte cultures conditioned
for 24 hr. Endostatin levels were quantified by ELISA and normalized to the protein content in the respective cell lysates. n = 9 independent
astrocyte preparations per genotype. Mean ± SEM is indicated. **, p < .01 by unpaired t test. (e) Endostatin levels in cell lysates from primary WT
or KO astrocyte cultures were measured by ELISA and normalized to the protein content. n = 8 independent astrocyte preparations per genotype.
Mean ± SEM is indicated. *, p < .05 by unpaired t test. (f) Transcript levels of the endostatin precursor collagen 18a in astrocyte cell lysates as
measured by qRT-PCR and given relative to transcript levels of actin. Log2(fold change) relative to WT is shown. Mean ± SEM is indicated. n = 7
independent astrocyte preparations per genotype
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corresponded with lower p-Erk levels as compared with the ipsilateral
hemispheres of KOs (Figure 4f,g).
To further corroborate the role of astrocytic SorCS2 in endostatin
release, we used primary astroglial cultures that express SorCS2 when
kept in serum-supplemented medium (Figure 5a,b). Substantiating our
findings from the MCAo experiments, SorCS2-deficient astrocytes
were able to normally secret multiple cytokines after PMA/ionomycin
stimulation when compared with WT cells (Figure 5c and Supporting
Information Figure S8). However, their ability to release endostatin
was significantly impaired (Figure 5d). Endostatin levels were also
lower in cell lysates from KO as compared with WT astrocytes
(Figure 5e). In conclusion, astrocytes were able to produce and release
endostatin in a process that depended on SorCS2. Transcript levels of
the endostatin precursor collagen XVIII were not different between
F IGURE 6 SorCS2 deficiency impairs post-stroke
angiogenesis. (a) Representative images of coronal brain
sections of WT and KO mice 21 days after MCAo. Mice
were injected with DyLight488-lectin (green) to visualize
blood vessels. In addition, the sections were immunostained
for GFAP (red; astrocytes) and NeuN (blue; neurons) and
counterstained with DAPI (grayscale). Left panels show
combined signals for all channels, while right panels show
DyLight488-lectin signal in grayscale. Dashed lines indicate
regions analyzed in (b–g); scar, glial scar region; peri, peri-
infarct region. Scale bars, 500 μm. (b) Representative images
of glial scar regions in ipsilateral hemispheres of WT and KO
mice brains as indicated in (a). Maximum intensity
projections of confocal z-sections are shown. Scale bar,
50 μm. (c) Quantification of brain areas covered by vessels
and vessels length in the glial scar region of WT and KO
brains 21 days after MCAo (as depicted in (b)). n = 7–8 mice
per genotype. Mean ± SEM is indicated. *, p < .05; **,
p < .01 by unpaired t test. (d) Representative images of peri-
infarct regions in ipsilateral hemispheres of WT and KO
mice brains as indicated in (a). Maximum intensity
projections of confocal z-sections are shown. Scale bar,
50 μm. (e) Quantification of brain areas covered by vessels
and vessels length in the peri-infarct regions of WT and KO
brains 21 days after MCAo (as depicted in (d)). n = 7–8 mice
per genotype. Mean ± SEM is indicated. *, p < .05 by
unpaired t test. (f) Representative images of contralateral
hemispheres of WT and KO mouse brains as indicated in (a).
Maximum intensity projections of confocal z-sections are
shown. Scale bar, 50 μm. (g) Quantification of brain areas
covered by vessels and vessels length in contralateral
hemispheres of WT and KO brains 21 days after MCAo
(as depicted in (f)). n = 7–8 mice per genotype. Mean ± SEM
is indicated
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the genotypes, suggesting a post-transcriptional mechanism of
SorCS2-controlled endostatin release from astrocytes (Figure 5f).
3.4 | SorCS2-dependent release of endostatin
promotes post-stroke angiogenesis
Next, we explored the consequence of SorCS2-induced production of
endostatin for post-stroke angiogenesis. To do so, we injected WT
and KO mice at 21 days after MCAo with DyLight 488-labeled lectin
to mark functional vessels (Figure 6a). This time point is commonly
used to study revascularization of the post-stroke murine brain (J.-Y.
Chen et al., 2017; Rust et al., 2019).
Ischemic stroke triggers angiogenesis in areas adjacent to the
lesion (Hayashi, Noshita, Sugawara, & Chan, 2003; Krupinski, Kaluza,
Kumar, Kumar, & Wang, 1994). In line with this concept, blood vessels
length was increased in the glial scar region in the WT brains, as com-
pared with the contralateral side (Supporting Information Figure S9).
However, this response was not seen in KO brains (Supporting
Information Figure S9). More detailed analysis revealed that the
length of the vessels but also the overall area covered by vessels were
significantly reduced in the glial scar area in KO mice as compared
with WTs (Figure 6b,c). A statistically significant decrease in vessel
length in KO as compared with WT brains was also seen in the peri-
infarct area (Figure 6d,e). No differences in vessel length and coverage
were seen comparing the contralateral hemispheres of WT and KO
mice (Figure 6f,g), strongly arguing that SorCS2 deficiency does not
influence blood vessels formation during ontogeny but only during
post-stroke angiogenesis. In summary, we uncovered a link between
SorCS2 activity, endostatin release, and angiogenesis in the post-
ischemic brain.
4 | DISCUSSION
Astrocytes are crucial players in stroke pathogenesis (reviewed in
Pekny et al., 2016). We now show that activated astrocytes surround-
ing the ischemic core induce expression of SorCS2, a remarkable find-
ing considering that expression of this sorting receptor in the brain
has so far only been reported in neurons. Possibly, induction of
SorCS2 expression in astrocytes is a pathophysiological response to
increased levels of TGF-β1 in the post-stroke brain, which induces
receptor gene transcription in astrocytes but not in neurons. While
activated astrocytes define both infarct size and post-lesion recovery
in stroke, SorCS2 deficiency had no impact on the ischemic lesion size.
Instead, SorCS2 appears to have a specialized role in promoting post-
stroke tissue regeneration, in particular in angiogenesis. While we
cannot rule out with certainty that neuronal activities of SorCS2 may
contribute to post-stroke phenotypes, all of our findings strongly
argue that its role in recovery after ischemic insult depends on astro-
cytic expression of the receptor.
Given the prominent role of astrocytes in the inflammatory brain
response, an impact of SorCS2 on their ability to release cytokines
may have been anticipated. Such a function had been shown for the
related VPS10P domain receptor sortilin in T-cells (Herda et al., 2012).
However, cytokine profiling in mouse brains and in activated primary
astrocytes failed to document any SorCS2-dependent alterations.
Rather, our studies uncovered the ability of SorCS2 to facilitate pro-
duction and/or release of endostatin from this cell type. Endostatin is
cleaved from its precursor collagen XVIII by various proteases, includ-
ing cathepsins and metalloproteinases (Felbor et al., 2000; Ferreras,
Felbor, Lenhard, Olsen, & Delaissé, 2000; Ma et al., 2007). To date, it
is not clear which protease plays the major role in generating endo-
statin in vivo and whether processing takes place intracellularly or in
the extracellular space. Thus, we can only speculate by what mecha-
nism SorCS2 promotes endostatin production. Other VPS10P domain
receptors sort cathepsins (Canuel, Korkidakis, Konnyu, & Morales,
2008), and SorCS2 may have a similar function in astrocytes to control
proteolysis of collagen XVIII by these proteases.
Because of the decisive role of endostatin in formation of new
blood vessels, it is tempting to speculate that impaired post-stroke
angiogenesis in SorCS2-deficient mice may be causally linked to
altered endostatin release from astrocytes in these mice. Endostatin
blocks extracellular matrix-dependent motility and morphogenesis in
numerous cell types (Kuo et al., 2001). Its anti-proliferative and anti-
migratory effects on endothelial cells profoundly inhibit angiogenesis
in tumor models (O'Reilly et al., 1997). Long-term treatment with
endostatin abolishes the pro-angiogenic effects of physical activity in
post-stroke mice (Gertz et al., 2006). In humans, high plasma levels of
endostatin after stroke predict a worse long-term functional outcome
(Navarro-Sobrino et al., 2011). We now show an increase in endoge-
nous endostatin levels in the ischemic brain as a physiological
response acutely after stroke (Figure 4). A similar surge in endostatin
levels after stroke has been observed by others in rats (Hou et al.,
2010) and rabbits (Tian, Chen, Cui, Xu, & Zhou, 2007). Increased post-
stroke release of endostatin seems counterintuitive given the need of
the injured brain to grow new vessels. However, previous studies indi-
cated that the levels of both pro- and anti-angiogenic factors are
induced after stroke and that these factors show dynamically regu-
lated expression profiles (Hayashi et al., 2003). For example, levels of
the angiogenesis inhibitor thrombospondin-1 transiently decrease
1 day after stroke to increase at 3 days post-ischemia. These findings
highlight important temporal aspects of orchestrating post-stroke
angiogenesis, and suggest crucial roles for anti-angiogenic factors,
such as endostatin and thrombospondin-1, in assuring proper angio-
genesis. Although the exact role of anti-angiogenic factors in recovery
from ischemia still needs further clarification, this hypothesis receives
strong support from our findings that revascularization is reduced in
SorCS2 mutant brains.
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